Akaal Pharma has completed recruitment for a Phase-2 clinical trial for atopic dermatitis and associated pruritus
Akaal Pharma Pty Ltd has completed recruitment for a Phase-2 clinical trial involving patients with atopic dermatitis and associated pruritus. Akaal Pharma Pty Limited (Akaal) today announced that it has completed recruitment of 140 patients for its Phase 2 clinical study to evaluate safety, tolerability and efficacy of topical 1% AKP-119 in atopic dermatitis participants with pruritus.